Tests ALN-HTT02 in adults with Huntington's disease
Tests a drug given into the spinal fluid in adults with Huntington's disease.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Key facts
- Where
- Edmonton, Montreal, Ottawa, and Vancouver, CanadaSee the 4 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 70 years old?
Source: NCT06585449, who can take part
Where in Canada
- EdmontonEdmonton, CanadaTaking people
- MontrealMontreal, CanadaTaking people
- OttawaOttawa, CanadaTaking people
- VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT06585449
- Record updated
- 15 October 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Inclusion: Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS).
Exclusion: Has received an investigational agent within the last 1 year or 5 half-lives (if known); Note: other protocol defined inclusion / exclusion criteria apply; Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening; Has primary or secondary immune compromise at screening due to infections, medical conditions, or chronic therapies; Has alanine aminotransferase or aspartate aminotransferase >2× upper limit of normal (ULN); Has an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m\^2 at screening.